Rebecca

Articles translated into German by Rebecca

• Self-determination on the HD journey: the role of Advanced Care Planning
• We are not alone, and are seeing more RED
• Huntington Study Group (HSG) Conference 2024 – Day 3
• Huntington Study Group (HSG) Conference 2024 – Day 2
• Huntington Study Group (HSG) Conference 2024 – Day 1
• 2024 HDBuzz Prize: Social Skills - The Hidden Gem in Improving Quality of Life for People with Huntington's disease?
• Announcing the 2024 HDBuzz Prize for Young Science Writers!
• Bringing HD Treatments to Market: The Role of Regulatory Oversight
• Interruptions are encouraged
• Highlighting a link between brain disorders on Ataxia Awareness Day
• Hope vs. hype: seeking truth in recent Prilenia headlines
• Mini brains grown in a dish shed light on Huntington’s disease and how we might treat it
• Hereditary Disease Foundation (HDF) conference 2024 – Day 4
• Hereditary Disease Foundation (HDF) conference 2024 – Day 3
• Hereditary Disease Foundation (HDF) conference 2024 – Day 1
• Hereditary Disease Foundation (HDF) conference 2024 – Day 2
• Blue skies for Skyhawk: Positive news from Phase 1 trial for SKY-0515
• Positive news from Wave Life Sciences SELECT-HD trial
• No pivot needed for PTC-518
• SURVEYOR opens the door for drugs that treat cognition
• The VIP section: velvet ropes for the brain and how to get in
• A sprinkling of good news for the treatment of HD chorea
• A new era for HDBuzz
• How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain
• Understanding expansions at the single cell level
• Huntington's Disease Therapeutics Conference 2024 - Day 3
• Huntington's Disease Therapeutics Conference 2024 - Day 1
• Huntington's Disease Therapeutics Conference 2024 - Day 2
• CRISPR-based drugs: one giant leap for mankind
• Steady progress from uniQure - promising data to end the year
• Putting it in print: GENERATION HD1 study results published
• Regulating repetition: Gaining control of CAG repeats could slow progression of Huntington’s disease
• Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
• Getting to the Root of Huntington's Disease: A Plant-Based Approach
• Could halting CAG expansions be a new treatment for HD?
• Drug to treat movement symptoms of HD approved by FDA
• Youthful competitors: young brain cells oust the old
• Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
• Roche Phase II GENERATION HD2 study underway
• Disappointing news from Novartis about branaplam and the VIBRANT-HD trial
• uniQure gets the green light to resume testing HD gene therapy
• Update on the PTC Therapeutics PIVOT-HD Trial
• Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
• Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
• Hereditary Disease Foundation (HDF) conference 2022 – Day 4
• Hereditary Disease Foundation (HDF) conference 2022 – Day 3
• Hereditary Disease Foundation (HDF) conference 2022 – Day 2
• Hereditary Disease Foundation (HDF) conference 2022 – Day 1
• Serious side effects reported for some people treated with the huntingtin-lowering drug AMT-130, currently in clinical trials
• Huntington’s disease therapeutics conference 2022 - Day 1
• Revisiting vitamin therapy for HD
• A spoonful of branaplam helps the huntingtin go down
• Oral drug may change the story for huntingtin lowering
• Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
• “Seeing” the toxic huntingtin protein in people with HD
• KINECT-HD trial shows valbenazine improves involuntary movements in Huntington's disease
• Real talk: Q&A with Roche about GENERATION-HD1
• Updates from the EHDN Meeting 2021
• Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing
• Unpacking recent gene therapy press
• Does blood hold the key to testing treatments earlier in HD patients?
• A first for CRISPR gene editing could have wider applications for human disease
• Scientists identify precisely how pridopidine works in models of Huntington’s disease
• Huntington’s disease clinical trial round up
• Huntington's disease therapeutics conference 2021 - Day 3
• Huntington's disease therapeutics conference 2021 - Day 2
• Huntington’s disease therapeutics conference 2021 - Day 1
• Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
• Sad News from Roche and Ionis - ASO Trial Halted Early
• GPR52: Exploring a new way to lower huntingtin
• Uncovering the dark side of DNA repair to design HD treatments
• Screening the entire genome for new drug targets for HD
• Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
• Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
• Treatment for neurological disorder could be repurposed for Huntington’s disease patients
• Updates from the EHDN Plenary Meeting 2020
• Sad news from the SIGNAL study: pepinemab does not influence HD symptoms
• When genes are unstable: targeting somatic instability in HD
• Working as a team: Changes in brain development mean some brain regions may be slacking off
• Caution urged for the use of gene-editing technology CRISPR
• HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
• Changing jobs: converting other cell types into neurons
• HD Young Adult Study defines the sweet spot: symptom-free with measurable changes
• Fountain of youth: HTT protein repairs neurons by maintaining youthful state
• Huntington’s disease therapeutics conference 2020 - Day 3
• Huntington’s disease therapeutics conference 2020 - Day 2
• New molecule can reverse the Huntington's disease mutation in lab models
• Huntington’s disease therapeutics conference 2020 - Day 1
• The third dimension: using minibrains to understand brain development changes in HD
• Unpacking Wave's PRECISION-HD2 huntingtin-lowering trial announcement
• Could molecular handcuffs lower the protein that causes Huntington's disease?
• Exciting new Huntingtin lowering tool described
• Details emerge of first Huntington’s disease gene therapy clinical trial
• Fresh Updates from First Huntingtin Lowering Study Publication
• An Updated Trial Design for Roche's Huntingtin Lowering Trial
• When interrupting is good: genetic hiccups that protect against Huntington's disease
• Huntington's disease therapeutics conference 2019 - Day 3
• Huntington's disease therapeutics conference 2019 - Day 2
• Huntington's disease therapeutics conference 2019 - Day 1
• Huntington's disease goes viral as UniQure inches ahead in gene therapy race
• Advances on many fronts in the battle against the protein that causes Huntington's disease
• HDSA FAQ on the Roche/Genentech RG6042 program
• Kids sometimes get Huntington’s disease too
• Roche announces details of its 'pivotal' huntingtin-lowering study
• Disappointing news from LEGATO-HD trial of laquinimod in Huntington's disease
• HDBuzz Enrolls in Enroll-HD
• First Dolly, now Piglet; a new Huntington’s disease pig knock-in model confirmed
• New collaboration seeks to speed Huntington's disease drug licensing
• HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
• Exciting Experiments in "Open Science" by Huntington's Researchers
• The structure of the protein that causes Huntington's disease, revealed
• Huntington's disease therapeutics conference 2018 - day 3
• Huntington's disease therapeutics conference 2018 - day 2
• Huntington's disease therapeutics conference 2018 - day 1
• An early role for the Huntington's disease gene – but don't believe all the headlines
• New interest in an old target
• Ask the expert: Q&A on the huntingtin-lowering trial program
• Success! ASO drug reduces levels of mutant protein in Huntington's disease patients
• Switch off the genome editor when you’re done
• A new way of thinking about trials to prevent Huntington's disease
• New roles for huntingtin: removing a healthy protein to understand its function
• Precision huntingtin-lowering drug trials target the mutant protein
• A step forward for gene editing: CRISPR-Cas9 and HD
• New study reveals a potential HD biomarker
• Has a "wonder drug" for dementia been discovered? (Spoiler alert: no.)
• Enemy at the gates – huntingtin disrupts nuclear transport
• FDA approves a new drug for symptoms of Huntington's disease
• Weeding out the truth: can cannabis improve Huntington’s?
• Sheep leading the flock: metabolism and biomarkers in HD